Vanguard Capital Management
VTGN icon

Vanguard Capital Management’s VistaGen Therapeutics VTGN Stock Holding History

Vanguard Capital Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$356K Hold
1,574,200
– – ﹤0.01% 3765
2026
Q1 		$900K Buy
+1,574,200
New +$956K ﹤0.01% 3571

Other funds holding VTGN

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management's VTGN Position: Q2 2026 in Review

Vanguard Capital Management held its VistaGen Therapeutics (VTGN) position steady in Q2 2026 at 1,574,200 shares worth $356K. The position accounts for ﹤0.01% of the portfolio, ranked #3765.

Vanguard Capital Management first reported a position in VTGN in Q1 2026 and has held it in 2 quarters since. The position peaked at $900K in Q1 2026. 46 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • Vanguard Capital Management held 1,574,200 shares of VistaGen Therapeutics worth $356K as of Q2 2026.
  • Vanguard Capital Management left its VistaGen Therapeutics share count unchanged in Q2 2026.
  • VistaGen Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3765 holding.
  • Vanguard Capital Management first reported a position in VistaGen Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's VistaGen Therapeutics position peaked at $900K in Q1 2026.
  • 46 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.